News for Arcturus Therapeutics Holdings Inc. (ARCT)

Revenue (FY 2024): $152.3 million, a decrease from $166.8 million in 2023.Revenue (Q4 2024): $22.8 million, down from $30.9 million in Q4 2023.Net Loss (FY 202

Mar 06, 2025 / 09:30PM GMTOperator Thank you for holding, ladies and gentlemen. We thank you for your patience and ask that you please continue to hold. Good da

Arcturus Therapeutics Holdings Inc (ARCT) is set to release its Q4 2024 earnings on Mar 6, 2025. The consensus estimate for Q4 2024 revenue is $44.65 million, a

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

PR NewswireWALTHAM, Mass. and SAN DIEGO, Feb. 14, 2025 - KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immuno

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

Arcturus Therapeutics stock hits 52-week low at $14.82

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Cathie Wood's ARK buys ARCT, TXG, and sells VEEV, EXAS stock

Cathie Wood's ARK trades Trade Desk and CRISPR stock, sells Unity

With over 80 key companies active in the RNA therapies space, the market is projected to grow due to advancements in mRNA, siRNA, and antisense...

Arcturus shares gain as William Blair affirms Outperform rating

Every investor aspires to see the stocks in their portfolio deliver substantial returns. Though trading is a game of probabilities, with both wins and losses, some investors manage to hit the jackpot.

The tide has gone out on ARK Invest's ETFs, and it doesn't look pretty.

Loading... Loading... Shares of Applied DNA Sciences, Inc. APDN fell sharply during Tuesday's session after the company announced the pricing of a $12 million ...